Fibrocystic breast changes. Diffuse cystic mastopathy
Conditions
Interventions
Intervention group: Intervention group: 600 mg N-acetyl cysteine tablets are taken once a day for 12 weeks..
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.Age above 18 years 2. Definitive diagnosis of fibrocystic breast 3. Consent to participate in the study 4. No history of any surgery in the breast area 5. No history of any kind of breast malignancy and other malignancies 6. Insensitivity to oral N-acetylcysteine medicine 7. Not receiving any non-routine medication during the intervention 8. Not taking medicine to reduce pain (medicines such as danazol, tamoxifen and bromocriptine) during the last three months 9. Absence of pregnancy or breastfeeding 10. Lack of menopause 11. Not taking psychiatric drugs
Exclusion criteria
Exclusion criteria: 1. Receiving any non-routine medication during the intervention 2. The need to perform breast surgery during the study 3. Lack of consent to continue participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In this study, the average cyst volume in the breast, quantitative CRP and numerical pain rating scale will be used. Zero means no pain and 10 means the worst pain condition. Timepoint: The variables are measured before and 12 weeks after the intervention. Method of measurement: The average volume of the breast cyst is measured by ultrasound and a small amount of CRP is given by the laboratory and the amount of pain is given by asking the patient and giving a score of 0 to 10. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaeze Kamrani Dastjerdi
Arak University of Medical Sciences
Outcome results
None listed